Clinical trialPhase 1 / Phase 2Not yet recruiting
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Not yet recruiting
- Study type
- Interventional
- Start
- 1 October 2026
- Expected end
- April 2030
- Enrollment
- 31 participants
- Sites
- 1
- Primary outcomes
- Dose limiting toxicities (DLTs) - Part A; Objective response (OR) - Part B
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try